Literature DB >> 10760116

Endothelin antagonists in renal disease.

A Benigni1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760116     DOI: 10.1046/j.1523-1755.2000.00023.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  5 in total

1.  Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.

Authors:  Nathan A Tullos; Nicholas J Stewart; Ryan Davidovich; Alejandro R Chade
Journal:  Nephrol Dial Transplant       Date:  2014-11-21       Impact factor: 5.992

Review 2.  Renoprotective therapy in patients with nondiabetic nephropathies.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats.

Authors:  C Thirunavukkarasu; Y Yang; V M Subbotin; S A K Harvey; J Fung; C R Gandhi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

4.  Prevention of cultured rat stellate cell transformation and endothelin-B receptor upregulation by retinoic acid.

Authors:  Xuedong Chi; Kristin Anselmi; Simon Watkins; Chandrashekhar R Gandhi
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor.

Authors:  Kentaro Ushijima; Hitoshi Ando; Yusuke Arakawa; Kenichi Aizawa; Chisato Suzuki; Ken Shimada; Shu-Ichi Tsuruoka; Akio Fujimura
Journal:  Pharmacol Res Perspect       Date:  2017-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.